Loading...

About Us

Board of Directors

Scott Maguire
Scott Maguire Non-Executive Chairman
SimonTallett
Simon Tallett Chief Development Officer
DmitryGenkin-colour
Dmitry Genkin
MosheMizrahy_newimage
Moshe Mizrahy
M. Scott Maguire (Non-Executive Chairman)

(MBA)


Mr. Maguire has over 30 years of global life sciences and healthcare investment banking, management and board experience, raising well in excess of $1billion as an executive and an advisor.


Mr. Maguire is a co-founder and board member of Cannaray Limited. Cannaray is a medical cannabis and cannabodiol company, operating in the UK and Germany. After closing on a £7.8 million Series A raise, Cannaray through acquisitions quickly became Europe’s second largest (in terms of revenues) cannabis company.


Having been Chairman and CEO of Xenetic Biosciences Inc (XBIO), Mr. Maguire turned a life science start-up with a collection of patents into a clinical stage company listed on NASDAQ, a listing he led in 2016. Mr Maguire raised approximately $35M from the private and public markets as well as $20M from strategic investors and has transacted license agreements for Xenetic worth $178M.


Mr. Maguire was a co-founder and board member of UK dialysis services, Renal Services Ltd. He led the fundraising from seed capital to Series C. Renal Services became the second largest private provider of dialysis services in the UK.  The business was exited via a trade sale to DaVita Inc in late 2020.


In 2002 he founded Healthcare Capital Partners Ltd, a healthcare and life science corporate finance and proprietary investment boutique which has been responsible for hundreds of millions in investments and exits since its founding. In 1996, he co-founded the Arthur Andersen global healthcare/life sciences corporate finance practice based in London which he assisted in building from 2 to 35 bankers globally. Scott started his banking career on Wall Street with Merrill Lynch in 1987.

Simon Tallett (Chief Development Officer)

Mr. Tallett serves as Chief Development Officer. He is B.Sc., MPharm, ABPI, GPhC. Simon has extensive experience in the Healthcare and Life Science areas. After international academic studies in the fields of Microbiology/Virology and Pharmacology, Simon spent several years in various Clinical Pharmacist roles including Aseptics, Cardiology, Nephrology, Respiratory and Immunology. Simon has previous experience in clinical research in the Louise Cootes Centre at Guys and St Thomas Hospital, where he designed and led a research project looking at the effects of smoking on the efficacy of Hydroxychloroquine uptake in Lupus patients – Published in Arthritis & Rheumatism Abstract Supplement of American journal of Rheumatology (Volume 54, Number 9, September 2006) and presented in Washington D.C.


Simon found his early medical passion in Paediatrics whilst working at Great Ormond Street Hospital, London. More recently interests have led him to pursue active roles campaigning for novel therapeutic approaches to be embraced in medicine. Now, as CEO and Founder of Perceptive Edge, Simon has been involved in a variety of pharmaceutical and life science companies – evaluating conceptual ideas and developing and establishing areas of growth and investment opportunities.


Simon holds a B.Sc. from the University of Western Ontario, Canada and Master’s in Pharmacy from University College London School of Pharmacy, England. Simon is a Member of GPhC (General Pharmaceutical Council) and ABPI (Association of British Pharmaceutical Industry).

Dmitry Genkin

Since 2006, Dr. Genkin has served as the Chairman of the Board of Pharmsynthez plc (MICEX: LIFE), an Eastern European pharmaceutical company specializing in the development of oncology drugs and manufacture of science-intensive substances. Since 2002, Dr. Genkin has served as a director of and on the scientific advisory board of Xenetic Biosciences, Inc. (NASDAQ: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics. Dr Genkin is co-founder and former director of VBI Vaccines Inc (NASDAQ: VBIV) – a clinical-stage biopharmaceutical company.

Moshe Mizrahy

Moshe Mizrahy co-founded InMode Ltd. (NASDAQ: INMD) in 2008 and has been our Chief Executive Officer and Chairman of the board of directors since inception. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd., a medical aesthetic device company based in Israel. Mr. Mizrahy was also the former chief executive officer of Home Skinovations Ltd., an international medical aesthetic consumer devices company active in the home use market, and is currently the chairman of its board since 2007. In addition to Home Skinovations Ltd., Mr. Mizrahy currently sits on the board of directors of the following companies: SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., Easy-Lap Ltd, O.B.-Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., New Forest Wood Products (2012) Ltd., M.N. Business Strategy Ltd., Silk’n Cure Ltd. and Himalaya Family Office Advising Ltd. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an MBA from Pace University, New York.